Dexa Group

JAKARTA — PT Fonko International Pharmaceuticals has recorded several key milestones in the development of oncology drug manufacturing in Indonesia. These achievements include securing European Union Good Manufacturing Practice (EU GMP) certification in 2025, developing a range of “first copy” products for cancer therapy, and obtaining halal certification for its entire oncology product line. This progress builds on Fonko’s ongoing commitment to expanding domestic production capacity for...

TANGERANG — PT Ferron Par Pharmaceuticals, a member of Dexa Group, has won the 2026 Indonesia Halal Industry Award (IHYA) from the Ministry of Industry of the Republic of Indonesia in the Large Industrial Enterprise Category, Subcategory of Best Pharmaceuticals and Traditional Medicines. This award recognizes Dexa Group’s consistency in implementing the Halal Product Assurance System (SJPH). To date, all of Dexa Group’s production facilities and products have been certified halal. This...

JAKARTA — Indonesia recorded 474,083 new cases and 283,299 deaths due to cancer, according to 2024 Global Cancer Observatory (GLOBOCAN) data. This situation underscores the critical role of Ferron Par Pharmaceuticals in expanding its support for cancer patients—from delivering access to medications to strengthening chemotherapy support facilities through the provision of Cytostatic Drug Preparation Units (TPO Sitostatika) in more than 10 hospitals across Indonesia, including the recent...

JAKARTA — Amid a series of natural disasters impacting various regions across Indonesia throughout 2026, Dexa Group, through its Corporate Social Initiative Dharma Dexa, continues to strengthen its commitment to safeguarding health and inspiring hope for affected communities. This step marks part of Dexa Group’s 57th-anniversary spirit to extend meaningful care tailored to the specific needs of each region. From medical supplies and shelter to preventive health protection and moral support,...

JAKARTA – For more than three decades, Dexa Group has consistently contributed to providing quality medicines for the Indonesian people through Obat Generik Berlogo/OGB (unbranded generics) Dexa. Today, OGB Dexa produces more than 2 billion units annually with over 140 SKUs to support the National Health Insurance (JKN) program. This contribution to ensuring the availability of quality and affordable medicines has been ongoing since production began in 1991. In 1991, Dexa Medica became the...

JAKARTA — Globally, the condition long known as polycystic ovary syndrome (PCOS) is estimated to affect more than 170 million women, or approximately one in eight women of reproductive age. The vast prevalence and far-reaching impact of this condition led to a global consensus published in The Lancet in 2026, proposing a name change from PCOS to polyendocrine metabolic ovarian syndrome (PMOS). This new nomenclature is considered to better reflect the multisystem nature of the disorder, which...